Wearlinq Raises $14M to Scale Its Wireless Clinical-Grade Heart Monito

Wearlinq has raised a $14 million Series A investment alongside $5 million in venture debt financing to accelerate commercialization of its wireless 6-lead ECG wearable, eWave. The funding was led by AIX Ventures with participation from SpringTide, Berkeley Catalyst Fund, Lightscape Partners, Solasta, Alumni Ventures, Amino Capital, Angelschool, LDV Partners, Maliam, XB Ventures, Celtic House Asia Partners Health, Device of Tomorrow Capital, NYX Ventures Partners and SmartLink Partners.

The San Francisco–based company develops eWave, a continuous, clinical-grade ECG monitoring device that pairs with a smartphone to deliver real-time cardiac data and reports of less than 48 hours to clinicians. Wearlinq highlights that the device can operate for more than five days on a single charge, offering an alternative to traditional wired monitors. The company states that eWave currently supports arrhythmia detection and intends to expand its clinical scope over time.

Konrad Morzkowski, co-founder and CEO of Wearlinq, noted the long-term clinical imperative for earlier cardiovascular detection, stating that “Even a 10% reduction in early heart disease death in the U.S. equates to over 100,000 lives saved. There is no bigger mission for us, and this new funding gives us the ability to scale eWave nationally.”

The new investment builds on a year of continued activity for the company. Wearlinq raised $6.7 million last year and expanded its capabilities through the acquisition of AMI Cardiac Monitoring, an ambulatory monitoring provider. In 2022, the company received FDA 510(k) clearance for its eWave Monitor, which is intended to support continuous cardiac monitoring for individuals who may be asymptomatic or experience transient symptoms such as syncope, palpitations, dizziness, shortness of breath, pre-syncope, lightheadedness, fatigue or anxiety.

With fresh capital and regulatory clearance in place, Wearlinq plans to accelerate national deployment of eWave and broaden its diagnostic utility, positioning the platform within a growing market for mobile cardiac monitoring solutions.

Click here for the original news story.